Skip to content
2000
Volume 26, Issue 6
  • ISSN: 1389-2037
  • E-ISSN: 1875-5550

Abstract

Migraine is a neurological disease that, while not inherently causing “chronic headaches,” can evolve into a chronic condition over time including major symptoms such as nausea, and light, sound, and allodynia, particularly in cases of frequent episodic migraine or due to factors such as medication overuse or inadequate management. This condition's complex pathophysiology makes treatment difficult. Genetics, trigeminovascular system activation, and cortical spreading depression are involved. Epidemiological research estimates that one in seven persons worldwide are affected, mostly women. Migraine prevalence has increased dramatically in recent decades; however, it varies by demographic and location. This review covers pharmaceutical and non-pharmacological migraine therapy methods and their future. Second-generation triptans have reduced side effects and administration issues, however, Zolmitriptan and Sumatriptan still treat migraines. Monoclonal antibodies that target calcitonin gene-related peptides may prevent migraines; however, their accessibility and safety are problems. Antiepileptics, beta-blockers, and neuromodulation devices are also available. Wearable technology offers customized monitoring and intervention. Precision medicine and gene-based medicines provide hope for tailored migraine treatments, but access, privacy, and informed consent raises ethical concerns. Stakeholder engagement must promote patient autonomy and well-being, responsible implementation, and equal access to novel therapies. A holistic and multidisciplinary approach is needed to manage migraines, taking into consideration present and future therapy developments and new challenges. Research, collaboration, and ethics can improve migraine outcomes and quality of life.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpps/10.2174/0113892037329429241123095325
2025-01-10
2025-10-14

  • From This Site

    /content/journals/cpps/10.2174/0113892037329429241123095325
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SteinerT.J. HusøyA. StovnerL.J. GBD2021: Headache disorders and global lost health – A focus on children, and a view forward.J. Headache Pain20242519110.1186/s10194‑024‑01795‑238831407
     [Google Scholar]
  2. MayansL. WallingA. Acute migraine headache: Treatment strategies.Am. Fam. Physician201897424325129671521
     [Google Scholar]
  3. PetersG.L. Migraine overview and summary of current and emerging treatment options.Am. J. Manag. Care201925Suppl 2S23S3430681821
     [Google Scholar]
  4. DeligianniC.I. SaccoS. EkizogluE. UluduzD. Gil-GouveiaR. MaassenVanDenBrinkA. OrnelloR. Sanchez-del-RioM. ReuterU. VersijptJ. de VriesT. HussainM. ZeraatkarD. LamplC. European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention - Part 2: flunarizine.J. Headache Pain202324112810.1186/s10194‑023‑01657‑337723437
     [Google Scholar]
  5. LamplC. VersijptJ. AminF.M. DeligianniC.I. Gil-GouveiaR. JassalT. MaassenVanDenBrinkA. OrnelloR. PaungarttnerJ. Sanchez-del-RioM. ReuterU. UluduzD. de VriesT. ZeraatkarD. SaccoS. European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention - Part 1: Amitriptyline.J. Headache Pain20232413910.1186/s10194‑023‑01573‑637038134
     [Google Scholar]
  6. RaffaelliB. García-AzorínD. BoucherieD.M. AminF.M. DeligianniC.I. Gil-GouveiaR. KirshS. LamplC. SaccoS. UluduzD. VersijptJ. MaassenVanDenBrinkA. ZeraatkarD. Sanchez-del-RioM. ReuterU. European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention – Part 3: topiramate.J. Headache Pain202324113410.1186/s10194‑023‑01671‑537814223
     [Google Scholar]
  7. VersijptJ. DeligianniC. HussainM. AminF. ReuterU. Sanchez-del-RioM. UluduzD. BoucherieD. ZeraatkarD. MaassenVanDenBrinkA. SaccoS. LamplC. Gil-GouveiaR. European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention - Part 4: propranolol.J. Headache Pain202425111910.1186/s10194‑024‑01826‑y39044170
     [Google Scholar]
  8. GrazziL. GiossiR. MontisanoD.A. CanellaM. MarcosanoM. AltamuraC. VernieriF. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: A retrospective, observational, multicenter, cohort study.J. Headache Pain20242511410.1186/s10194‑024‑01721‑638308209
     [Google Scholar]
  9. MenshawyA. AhmedH. IsmailA. AbushoukA.I. GhanemE. PallantiR. NegidaA. Intranasal sumatriptan for acute migraine attacks: A systematic review and meta-analysis.Neurol. Sci.2018391314410.1007/s10072‑017‑3119‑y28942578
     [Google Scholar]
  10. Tfelt-HansenP.C. Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: A review based on the GSK Trial Register.J. Headache Pain201112439940310.1007/s10194‑011‑0327‑321437713
     [Google Scholar]
  11. CharlesworthB. DowsonA.J. Review of zolmitriptan and its clinical applications in migraine.Expert Opin. Pharmacother.200237993100510.1517/14656566.3.7.99312083998
     [Google Scholar]
  12. BigalM.E. KurthT. HuH. SantanelloN. LiptonR.B. Migraine and cardiovascular disease.Neurology200972211864187110.1212/WNL.0b013e3181a7122019470970
     [Google Scholar]
  13. WangY.F. WangS.J. Hypertension and migraine: Time to revisit the evidence.Curr. Pain Headache Rep.20212595810.1007/s11916‑021‑00976‑x34269909
     [Google Scholar]
  14. LiptonR.B. CroopR. StockD.A. MadoniaJ. ForshawM. LovegrenM. MosherL. CoricV. GoadsbyP.J. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: A phase 3, double-blind, randomised, placebo-controlled multicentre trial.Lancet Neurol.202322320921710.1016/S1474‑4422(22)00517‑836804093
     [Google Scholar]
  15. CroopR. GoadsbyP.J. StockD.A. ConwayC.M. ForshawM. StockE.G. CoricV. LiptonR.B. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: A randomised, phase 3, double-blind, placebo-controlled trial.Lancet20193941020073774510.1016/S0140‑6736(19)31606‑X31311674
     [Google Scholar]
  16. WhealyM. BeckerW.J. The 5-HT1B and 5-HT1D agonists in acute migraine therapy: Ergotamine, dihydroergotamine, and the triptans.Handb. Clin. Neurol.2024199174210.1016/B978‑0‑12‑823357‑3.00008‑238307644
     [Google Scholar]
  17. OngJ.J.Y. De FeliceM. Migraine treatment: Current acute medications and their potential mechanisms of action.Neurotherapeutics201815227429010.1007/s13311‑017‑0592‑129235068
     [Google Scholar]
  18. PooleR.K. PooleD.H. Impact of ergot alkaloids on female reproduction in domestic livestock species.Toxins (Basel)201911636410.3390/toxins1106036431234268
     [Google Scholar]
  19. DuongS. BozzoP. NordengH. EinarsonA. Safety of triptans for migraine headaches during pregnancy and breastfeeding.Can. Fam. Physician201056653753920547518
     [Google Scholar]
  20. MasengaS.K. KiraboA. Hypertensive heart disease: Risk factors, complications and mechanisms.Front. Cardiovasc. Med.202310120547510.3389/fcvm.2023.120547537342440
     [Google Scholar]
  21. PakfetratM. RasekhiA. EftekhariF. HashemiN. RoozbehJ. TorabineghadS. MalekmakanL. Ergotamine-induced acute tubulo-interstitial nephritis.Saudi J. Kidney Dis. Transpl.201324598198310.4103/1319‑2442.11810024029265
     [Google Scholar]
  22. ClausenM.F. RørthR. Torp-PedersenC. WestergaardL.M. WeekeP.E. GislasonG. KøberL. FosbølE. KristensenS.L. Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine.BMC Cardiovasc. Disord.202121162210.1186/s12872‑021‑02439‑y34963443
     [Google Scholar]
  23. OliveiraR. Gil-GouveiaR. PuleddaF. CGRP-targeted medication in chronic migraine - Systematic review.J. Headache Pain20242515110.1186/s10194‑024‑01753‑y38575868
     [Google Scholar]
  24. SchoenenJ. Van DyckeA. VersijptJ. PaemeleireK. Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: A narrative review.J. Headache Pain20232419910.1186/s10194‑023‑01637‑737528353
     [Google Scholar]
  25. NegroA. MartellettiP. Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies.Expert Rev. Neurother.201919876977610.1080/14737175.2019.162174931109209
     [Google Scholar]
  26. MuddamM.R. ObajeunO.A. AbazaA. JaramilloA.P. Sid IdrisF. Anis ShaikhH. VahoraI. MoparthiK.P. Al RushaidiM.T. NathT.S. Efficacy and safety of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies in preventing migraines: A systematic review.Cureus2023159e4556010.7759/cureus.4556037868560
     [Google Scholar]
  27. MavridisT. DeligianniC. KaragiorgisG. DaponteA. BrezaM. MitsikostasD. Monoclonal antibodies targeting CGRP: From clinical studies to real-world evidence - What do we know so far?Pharmaceuticals (Basel)202114770010.3390/ph1407070034358126
     [Google Scholar]
  28. ShahT. BedrinK. TinsleyA. Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review.Front Pain Res. (Lausanne)20234113023910.3389/fpain.2023.1130239
     [Google Scholar]
  29. SilbersteinS.D. Preventive migraine treatment.Continuum (Minneap. Minn.)2015214 Headache97398910.1212/CON.000000000000019926252585
     [Google Scholar]
  30. JohnsonB. FreitagF.G. New approaches to shifting the migraine treatment paradigm.Front. Pain Res. (Lausanne)2022387317910.3389/fpain.2022.873179
     [Google Scholar]
  31. DeenM. CorrentiE. KammK. KeldermanT. PapettiL. Rubio-BeltránE. VigneriS. EdvinssonL. Maassen Van Den BrinkA. Blocking CGRP in migraine patients – A review of pros and cons.J. Headache Pain20171819610.1186/s10194‑017‑0807‑128948500
     [Google Scholar]
  32. AssasM.B. Anti-migraine agents from an immunological point of view.J. Transl. Med.20211912310.1186/s12967‑020‑02681‑633407608
     [Google Scholar]
  33. SangalliL. BrazzoliS. Calcitonin gene-related peptide (CGRP)-targeted treatments - New therapeutic technologies for migraine.Future Pharmacol.20233111713110.3390/futurepharmacol3010008
     [Google Scholar]
  34. LamplC. MaassenVanDenBrinkA. DeligianniC.I. Gil-GouveiaR. JassalT. Sanchez-del-RioM. ReuterU. UluduzD. VersijptJ. ZeraatkarD. SaccoS. The comparative effectiveness of migraine preventive drugs: A systematic review and network meta-analysis.J. Headache Pain20232415610.1186/s10194‑023‑01594‑137208596
     [Google Scholar]
  35. FavoniV. GianiL. Al-HassanyL. AsioliG.M. ButeraC. de BoerI. GuglielmettiM. KoniariC. MavridisT. VaikjärvM. VerhagenI. VerzinaA. ZickB. MartellettiP. SaccoS. CGRP and migraine from a cardiovascular point of view: What do we expect from blocking CGRP?J. Headache Pain20192012710.1186/s10194‑019‑0979‑y30866804
     [Google Scholar]
  36. RaffaelliB. TerhartM. OvereemL.H. MecklenburgJ. NeebL. SteinickeM. ReuterU. Migraine evolution after the cessation of CGRP (-receptor) antibody prophylaxis: A prospective, longitudinal cohort study.Cephalalgia2022424-532633410.1177/03331024211046617
     [Google Scholar]
  37. TzankovaV. BeckerW.J. ChanT.L.H. Pharmacologic prevention of migraine.CMAJ20231955E187E19210.1503/cmaj.221607
     [Google Scholar]
  38. BiscettiL. CrestaE. CupiniL.M. CalabresiP. SarchielliP. The putative role of neuroinflammation in the complex pathophysiology of migraine: From bench to bedside.Neurobiol. Dis.202318010607210.1016/j.nbd.2023.10607236907522
     [Google Scholar]
  39. MalhotraR. Understanding migraine: Potential role of neurogenic inflammation.Ann. Indian Acad. Neurol.201619217518210.4103/0972‑2327.18230227293326
     [Google Scholar]
  40. LionettoL. CipollaF. GuglielmettiM. MartellettiP. Fremanezumab for the prevention of chronic and episodic migraine.Drugs Today2019554265-27627610.1358/dot.2019.55.4.2970909
     [Google Scholar]
  41. MullenersW.M. KimB.K. LáinezM.J.A. Lanteri-MinetM. Pozo-RosichP. WangS. Tockhorn-HeidenreichA. AuroraS.K. NicholsR.M. Yunes-MedinaL. DetkeH.C. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): A multicentre, randomised, double-blind, placebo- controlled, phase 3b trial.Lancet Neurol.2020191081482510.1016/S1474‑4422(20)30279‑932949542
     [Google Scholar]
  42. AshinaM. Lanteri-MinetM. Pozo-RosichP. EttrupA. ChristoffersenC.L. JosiassenM.K. PhulR. SperlingB. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): A multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.Lancet Neurol.202221759760710.1016/S1474‑4422(22)00185‑535716692
     [Google Scholar]
  43. HolzerP. Holzer-PetscheU. Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine.Front. Physiol.20221282000610.3389/fphys.2021.82000635087426
     [Google Scholar]
  44. Rivera-MancillaE. VillalónC.M. MaassenVanDenBrinkA. CGRP inhibitors for migraine prophylaxis: A safety review.Expert Opin. Drug Saf.202019101237125010.1080/14740338.2020.181122932811190
     [Google Scholar]
  45. PallapothuM.R. Quintana MariñezM.G. ChakkeraM. RaviN. RamarajuR. VatsA. NairA.R. BandhuA.K. KoiralaD. MohammedL. Long-Term management of migraine with onabotulinumtoxinA (Botox) vs calcitonin gene-related peptide antibodies (Anti-CGRP).Cureus20231510e4669610.7759/cureus.4669638021691
     [Google Scholar]
  46. HubigL.T. SmithT. ChuaG.N. LloydA.J. PowellL. JohnstonK. HarrisL. L’ItalienG. CoricV. LoS.H. A stated preference survey to explore patient preferences for novel preventive migraine treatments.Headache20226291187119710.1111/head.1438636047857
     [Google Scholar]
  47. NguyenJ.L. MunshiK. PeasahS.K. SwartE.C.S. KohliM. HendersonR. GoodC.B. Trends in utilization and costs of migraine medications, 2017–2020.J. Headache Pain202223111110.1186/s10194‑022‑01476‑y36031609
     [Google Scholar]
  48. ShaterianN. ShaterianN. GhanaatpishehA. AbbasiF. DanialiS. JahromiM.J. SanieM.S. AbdoliA. Botox (OnabotulinumtoxinA) for treatment of migraine symptoms: A systematic review.Pain Res. Manag.2022202211510.1155/2022/328444635401888
     [Google Scholar]
  49. BeckerW.J. Botulinum toxin in the treatment of headache.Toxins (Basel)2020121280310.3390/toxins1212080333348571
     [Google Scholar]
  50. GiriS. TronvikE. LindeM. PedersenS.A. HagenK. Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis.Cephalalgia202343410.1177/03331024231156922
     [Google Scholar]
  51. CorasanitiM.T. BagettaG. NicoteraP. TarsitanoA. ToninP. SandriniG. LawrenceG.W. ScuteriD. Safety of Onabotulinumtoxin A in chronic migraine: A systematic review and meta-analysis of randomized clinical trials.Toxins (Basel)202315533210.3390/toxins1505033237235366
     [Google Scholar]
  52. FrankF. UlmerH. SidoroffV. BroessnerG. CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis.Cephalalgia20214111-121222123910.1177/03331024211018137
     [Google Scholar]
  53. DurhamP.L. CadyR. Insights into the mechanism of onabotulinumtoxinA in chronic migraine.Headache201151101573157710.1111/j.1526‑4610.2011.02022.x22082429
     [Google Scholar]
  54. BursteinR. BlumenfeldA.M. SilbersteinS.D. Manack AdamsA. BrinM.F. Mechanism of action of OnabotulinumtoxinA in chronic migraine: A narrative review.Headache20206071259127210.1111/head.1384932602955
     [Google Scholar]
  55. GiulianoF. DenysP. JoussainC. Safety and effectiveness of repeated botulinum toxin a intracavernosal injections in men with erectile dysfunction unresponsive to approved pharmacological treatments: Real-world observational data.Toxins (Basel)202315638210.3390/toxins1506038237368683
     [Google Scholar]
  56. DhengareA.S. FulmaliD.G. The development of psychiatric illness and chemoprophylaxis of botulinum toxin in migraine: A narrative review.Cureus20221412e3299810.7759/cureus.3299836712737
     [Google Scholar]
  57. WitmanowskiH. BłochowiakK. The whole truth about botulinum toxin – A review.Postepy Dermatol. Alergol.202037685386110.5114/ada.2019.8279533603602
     [Google Scholar]
  58. EnglishR.S. RuizS. Use of botulinum toxin for androgenic alopecia: A systematic review.Skin Appendage Disord.2022829310010.1159/00051857435415183
     [Google Scholar]
  59. MooreR.A. WiffenP.J. DerryS. MaguireT. RoyY.M. TyrrellL. Non-prescription (OTC) oral analgesics for acute pain - an overview of Cochrane reviews.Cochrane Libr.2015201511CD01079410.1002/14651858.CD010794.pub226544675
     [Google Scholar]
  60. SuthisisangC.C. PoolsupN. SuksomboonN. LertpipopmethaV. TepwitukgidB. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine.Headache201050580881810.1111/j.1526‑4610.2010.01635.x20236345
     [Google Scholar]
  61. DerryS. RabbieR. MooreR.A. Diclofenac with or without an antiemetic for acute migraine headaches in adults.Cochrane Libr.201320195CD00878310.1002/14651858.CD008783.pub323633360
     [Google Scholar]
  62. GunaydinC. BilgeS.S. Effects of nonsteroidal anti-inflammatory drugs at the molecular level.Eurasian J. Med.201850211612110.5152/eurasianjmed.2018.001030002579
     [Google Scholar]
  63. SohailR. MathewM. PatelK.K. ReddyS.A. HaiderZ. NariaM. HabibA. AbdinZ.U. Razzaq ChaudhryW. AkbarA. Effects of non-steroidal anti-inflammatory drugs (NSAIDs) and gastroprotective NSAIDs on the gastrointestinal tract: A narrative review.Cureus2023154e3708010.7759/cureus.3708037153279
     [Google Scholar]
  64. DemaagdG. The pharmacological management of migraine, part 1: Overview and abortive therapy.P T200833740441619750119
     [Google Scholar]
  65. SuthisisangC. PoolsupN. KittikulsuthW. PudchakanP. WiwatpanichP. Efficacy of low-dose ibuprofen in acute migraine treatment: Systematic review and meta-analysis.Ann. Pharmacother.200741111782179110.1345/aph.1K12117878396
     [Google Scholar]
  66. IngledueV.F. MounseyA. PURLs: treating migraine: The case for aspirin.J. Fam. Pract.2014632949624527476
     [Google Scholar]
  67. BerryH. BloomB. HamiltonE.B. SwinsonD.R. Naproxen sodium, diflunisal, and placebo in the treatment of chronic back pain.Ann. Rheum. Dis.198241212913210.1136/ard.41.2.1296462116
     [Google Scholar]
  68. AltmanR. BoschB. BruneK. PatrignaniP. YoungC. Advances in NSAID development: Evolution of diclofenac products using pharmaceutical technology.Drugs201575885987710.1007/s40265‑015‑0392‑z25963327
     [Google Scholar]
  69. WatkinsA.K. GeeM.E. BrownJ.N. Efficacy and safety of levetiracetam for migraine prophylaxis: A systematic review.J. Clin. Pharm. Ther.201843446747510.1111/jcpt.1271529781197
     [Google Scholar]
  70. WoldeamanuelY.W. OliveiraA.B.D. What is the efficacy of aerobic exercise versus strength training in the treatment of migraine? A systematic review and network meta-analysis of clinical trials.J. Headache Pain202223113410.1186/s10194‑022‑01503‑y36229774
     [Google Scholar]
  71. ParkS.P. KwonS.H. Cognitive effects of antiepileptic drugs.J. Clin. Neurol.2008439910610.3988/jcn.2008.4.3.9919513311
     [Google Scholar]
  72. D’AmicoD. TepperS.J. D’AmicoD. Prophylaxis of migraine: General principles and patient acceptance.Neuropsychiatr. Dis. Treat.2008461155116710.2147/NDT.S349719337456
     [Google Scholar]
  73. VukovićV. Lovrencić-HuzjanA. Bosnar-PuretićM. DemarinV. The efficacy of gabapentin in migraine prophylaxis: An observational open label study.Acta Clin. Croat.200948214515119928412
     [Google Scholar]
  74. Jiménez-HernándezM.D. Torrecillas NárvaezM.D. Friera AcebalG. Effectiveness and safety of gabapentin in the preventive treatment of migraine.Rev. Neurol.200235760360612389143
     [Google Scholar]
  75. HaganJ.C. EverettE. ChamberlainT. Compounded beta-blocker nasal spray for treatment of acute migraine: A new therapeutic modality.Int. J. Pharm. Compd.202024319419732401737
     [Google Scholar]
  76. LohN.R. WhitehouseW.P. HowellsR. What is new in migraine management in children and young people?Arch. Dis. Child.2022107121067107210.1136/archdischild‑2021‑32237335190383
     [Google Scholar]
  77. AmiriP. KazeminasabS. NejadghaderiS.A. MohammadinasabR. PourfathiH. Araj-KhodaeiM. SullmanM.J.M. KolahiA.A. SafiriS. Migraine: A review on its history, global epidemiology, risk factors, and comorbidities.Front. Neurol.20221280060510.3389/fneur.2021.80060535281991
     [Google Scholar]
  78. DaneshA. GottschalkP.C.H. Beta-blockers for migraine prevention: A review article.Curr. Treat. Options Neurol.20192142010.1007/s11940‑019‑0556‑330903383
     [Google Scholar]
  79. DuanJ. LaiJ. WangD. ZhouW. HuangM. HuS. XuY. LuJ. Topiramate precipitating a manic episode in a bipolar patient comorbid with binge eating disorder.Medicine (Baltimore)20199817e1528710.1097/MD.000000000001528731027088
     [Google Scholar]
  80. MacfarlaneA. GreenhalghT. Sodium valproate in pregnancy: What are the risks and should we use a shared decision-making approach?BMC Pregnancy Childbirth201818120010.1186/s12884‑018‑1842‑x29859057
     [Google Scholar]
  81. BornandD. ReinauD. JickS.S. MeierC.R. β-blockers and the risk of depression: A matched case-control study.Drug Saf.202245218118910.1007/s40264‑021‑01140‑535044637
     [Google Scholar]
  82. HaghdoostF. ToghaM. Migraine management: Non-pharmacological points for patients and health care professionals.Open Med. (Wars.)20221711869188210.1515/med‑2022‑0598
     [Google Scholar]
  83. MaxwellS.R.J. Rational prescribing: The principles of drug selection.Clin. Med. (Lond.)201616545946410.7861/clinmedicine.16‑5‑45927697811
     [Google Scholar]
  84. PakR.J. KuJ.B. Abd-ElsayedA. Neuromodulation for craniofacial pain and headaches.Biomedicines202311123328
     [Google Scholar]
  85. LiptonR.B. PearlmanS.H. Transcranial magnetic simulation in the treatment of migraine.Neurotherapeutics20107220421210.1016/j.nurt.2010.03.00220430320
     [Google Scholar]
  86. SimonB. BlakeJ. Mechanism of action of non-invasive cervical vagus nerve stimulation for the treatment of primary headaches.Am. J. Manag. Care201723Suppl 17S312S31629144716
     [Google Scholar]
  87. KramerJ. HayekS. LevyR. Neuromodulation treatments for migraine: A contemporary update.Curr. Opin. Anaesthesiol.202437559760310.1097/ACO.000000000000141439011719
     [Google Scholar]
  88. ShenM. LiC. WeiX. ZhangL. LiY. WuH. ZhangX. DongZ. GaoS. MaY. MaY. Transcranial magnetic stimulation as a therapy for migraine: An overview of systematic reviews.J. Pain Res.2023163133314410.2147/JPR.S41699337724171
     [Google Scholar]
  89. ZhongJ. LanW. FengY. YuL. XiaoR. ShenY. ZouZ. HouX. Efficacy of repetitive transcranial magnetic stimulation on chronic migraine: A meta-analysis.Front. Neurol.202213105009010.3389/fneur.2022.105009036504667
     [Google Scholar]
  90. SongD. LiP. WangY. CaoJ. Noninvasive vagus nerve stimulation for migraine: A systematic review and meta-analysis of randomized controlled trials.Front. Neurol.202314119006210.3389/fneur.2023.119006237251233
     [Google Scholar]
  91. SilbersteinS.D. CalhounA.H. LiptonR.B. GrosbergB.M. CadyR.K. DorlasS. SimmonsK.A. MullinC. LieblerE.J. GoadsbyP.J. SaperJ.R. CalhounA.H. CadyR.K. DexterJ. SilbersteinS.D. YoungW. MarmuraM. Nahas-GeigerS. Da SilvaA. SaperJ. WeintraubJ. PrestegaardA. SinkaE. GrosbergB. VollbrachtS. IssaS. LiptonR. MullinK. PavlovicJ. RobbinsM. GoadsbyP. GelfandA. EllerM. Chronic migraine headache prevention with noninvasive vagus nerve stimulation.Neurology201687552953810.1212/WNL.000000000000291827412146
     [Google Scholar]
  92. MillerS. WatkinsL. MatharuM. Long-term outcomes of occipital nerve stimulation for chronic migraine: A cohort of 53 patients.J. Headache Pain20161716810.1186/s10194‑016‑0659‑027475100
     [Google Scholar]
  93. Carrondo CottinS. GallaniN. CantinL. Prud’HommeM. Occipital nerve stimulation for non-migrainous chronic headaches: A systematic review protocol.Syst. Rev.20198118110.1186/s13643‑019‑1101‑x31331392
     [Google Scholar]
  94. MontenegroM.M. KissoonN.R. Long term outcomes of occipital nerve stimulation.Front. Pain Res. (Lausanne)20234105476410.3389/fpain.2023.1054764
     [Google Scholar]
  95. MoissetX. PereiraB. Ciampi de AndradeD. FontaineD. Lantéri-MinetM. MawetJ. Neuromodulation techniques for acute and preventive migraine treatment: A systematic review and meta-analysis of randomized controlled trials.J. Headache Pain202021114210.1186/s10194‑020‑01204‑433302882
     [Google Scholar]
  96. StubberudA. LindeM. Digital technology and mobile health in behavioral migraine therapy: A narrative review.Curr. Pain Headache Rep.201822106610.1007/s11916‑018‑0718‑030066141
     [Google Scholar]
  97. GazeraniP. Intelligent digital twins for personalized migraine care.J. Pers. Med.2023138125510.3390/jpm1308125537623505
     [Google Scholar]
  98. IngvaldsenS.H. TronvikE. BrennerE. WinnbergI. OlsenA. GravdahlG.B. StubberudA. A biofeedback app for migraine: Development and usability study.JMIR Form. Res.202157e2322910.2196/2322934319243
     [Google Scholar]
  99. SiirtolaP. KoskimäkiH. MönttinenH. RöningJ. Using sleep time data from wearable sensors for early detection of migraine attacks.Sensors (Basel)2018185137410.3390/s18051374
     [Google Scholar]
  100. AshinaM. PhulR. KhodaieM. LöfE. FloreaI. A monoclonal antibody to PACAP for migraine prevention.N. Engl. J. Med.2024391980080910.1056/NEJMoa2314577
     [Google Scholar]
  101. GaulC. FörderreutherS. Sumatriptan 3 mg subcutaneous.Nervenarzt202293661261710.1007/s00115‑021‑01189‑834557933
     [Google Scholar]
  102. DooleyM. FauldsD. Rizatriptan: A review of its efficacy in the management of migraine.Drugs199958469972310.2165/00003495‑199958040‑0001310551439
     [Google Scholar]
  103. CadyR. CrawfordG. AhrensS. HairwassersD. GetsonA. VisserW.H. LinesC. Long-term efficacy and tolerability of rizatriptan wafers in migraine.MedGenMed200133111549974
     [Google Scholar]
  104. DienerH.C. JansenJ.P. RechesA. PascualJ. PiteiD. SteinerT.J. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: A multicentre, randomised, double-blind, placebo-controlled comparison.Eur. Neurol.20024729910710.1159/00004796011844898
     [Google Scholar]
  105. YangY. ChenM. WuD. SunY. JiangF. ChenZ. WangZ. Optimal dose of erenumab for preventive treatment of episodic migraine: A systematic review and meta-analysis.Curr. Neuropharmacol.202220246047010.2174/1570159X1966621082310491634429056
     [Google Scholar]
  106. FerrariM.D. DienerH.C. NingX. GalicM. CohenJ.M. YangR. MuellerM. AhnA.H. SchwartzY.C. Grozinski-WolffM. JankaL. AshinaM. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): A randomised, double-blind, placebo-controlled, phase 3b trial.Lancet2019394102031030104010.1016/S0140‑6736(19)31946‑431427046
     [Google Scholar]
  107. DetkeH.C. GoadsbyP.J. WangS. FriedmanD.I. SelzlerK.J. AuroraS.K. Galcanezumab in chronic migraine.Neurology20189124e2211e222110.1212/WNL.000000000000664030446596
     [Google Scholar]
  108. YuS. KimB.K. GuoA. KimM.H. ZhangM. WangZ. LiuJ. MoonH.S. TanG. YangQ. McGrathD. HannaM. StockD.A. GaoY. CroopR. LuZ. Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: A phase 3, double-blind, randomised, placebo-controlled trial.Lancet Neurol.202322647648410.1016/S1474‑4422(23)00126‑637210098
     [Google Scholar]
  109. LiptonR.B. DodickD.W. AilaniJ. LuK. FinneganM. SzegediA. TrugmanJ.M. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine.JAMA2019322191887189810.1001/jama.2019.1671131742631
     [Google Scholar]
  110. BeckerW.J. ChristieS.N. LedouxS. BinderC. Topiramate prophylaxis and response to triptan treatment for acute migraine.Headache20064691424143010.1111/j.1526‑4610.2006.00531.x17040339
     [Google Scholar]
  111. AshtariF. ShaygannejadV. AkbariM. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis.Acta Neurol. Scand.2008118530130510.1111/j.1600‑0404.2008.01087.x18713156
     [Google Scholar]
  112. Doyle StraussL. WeizenbaumE. LoderE.W. RizzoliP.B. Amitriptyline dose and treatment outcomes in specialty headache practice: A retrospective cohort study.Headache201656101626163410.1111/head.1298727775149
     [Google Scholar]
  113. BaeJ. SungH.K. KwonN.Y. GoH.Y. KimT. ShinS.M. LeeS. Cognitive behavioral therapy for migraine headache: A systematic review and meta-analysis.Medicina (Kaunas)20215814410.3390/medicina5801004435056352
     [Google Scholar]
  114. Pérez-MuñozA. BuseD.C. AndrasikF. Behavioral interventions for migraine.Neurol. Clin.201937478981310.1016/j.ncl.2019.07.00331563233
     [Google Scholar]
  115. FrankD.L. KhorshidL. KifferJ.F. MoravecC.S. McKeeM.G. Biofeedback in medicine: Who, when, why and how?Ment. Health Fam. Med.201072859122477926
     [Google Scholar]
  116. RasmussenL. PoulsenC.W. KampmannU. SmedegaardS.B. OvesenP.G. FuglsangJ. Diet and healthy lifestyle in the management of gestational diabetes mellitus.Nutrients20201210305010.3390/nu1210305033036170
     [Google Scholar]
  117. Carneiro-BarreraA. Amaro-GaheteF.J. Guillén-RiquelmeA. Jurado-FasoliL. Sáez-RocaG. Martín-CarrascoC. Buela-CasalG. RuizJ.R. Effect of an interdisciplinary weight loss and lifestyle intervention on obstructive sleep apnea severity.JAMA Netw. Open202254e22821210.1001/jamanetworkopen.2022.821235452108
     [Google Scholar]
  118. ChengJ. LiF. LaiY. ChenJ. SunX. XiangL. JiangP. WuS. XiaoY. ZhouL. LuoR. ZhaoX. LiuY. Association of stress management skills and stressful life events with allergy risk: A case-control study in southern China.BMC Public Health2021211127910.1186/s12889‑021‑11333‑334193097
     [Google Scholar]
  119. WangM. LiuW. GeJ. LiuS. The immunomodulatory mechanisms for acupuncture practice.Front. Immunol.202314114771810.3389/fimmu.2023.114771837090714
     [Google Scholar]
  120. AnheyerD. KloseP. LaucheR. SahaF.J. CramerH. Yoga for treating headaches: A systematic review and meta-analysis.J. Gen. Intern. Med.202035384685410.1007/s11606‑019‑05413‑931667736
     [Google Scholar]
  121. ChaibiA. TuchinP.J. RussellM.B. Manual therapies for migraine: A systematic review.J. Headache Pain201112212713310.1007/s10194‑011‑0296‑621298314
     [Google Scholar]
  122. PirthirajA. BhagwanR. The psychosocial impact of migraines on women and alternative therapies for migraine management.Health SA202328224910.4102/hsag.v28i0.2249
     [Google Scholar]
/content/journals/cpps/10.2174/0113892037329429241123095325
Loading
Advances in Migraine Treatment: A Comprehensive Clinical Review
Curr. Protein Pept. Sci. 26, 422 (2025); https://doi.org/10.2174/0113892037329429241123095325
/content/journals/cpps/10.2174/0113892037329429241123095325
/content/journals/cpps/10.2174/0113892037329429241123095325
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): CGRP antagonists; chronic headaches; gene therapy; Migraine; monoclonal antibodies; non-pharmacological approaches

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test